'Safeguards' slowing down access to breakthrough drugs in India

New drugs are not reaching low and middle income countries. A study shows many medicines take years to become accessible globally. India's regulatory system needs to mature for quicker access to breakthrough therapies. Stronger intellectual property protection and global standardisation are key. This will help reduce delays in drug availability for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zm562ih
via IFTTT

Read More

Telangana’s loss is Andhra’s gain as pharma companies expand in Kurnool

Sigachi Industries and Virupaksha Organics are relocating expansion projects to Andhra Pradesh. They will establish new manufacturing units in Kurnool district's Orvakal Industrial Park. This move follows Telangana's decision to abandon its Pharma City plan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HoI8ZSY
via IFTTT

Read More

Respiratory drug sales peak in November amid worsening AQI

India's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previous years. This trend highlights a strong link between pollution and illness. States like Uttar Pradesh and Uttarakhand saw significant sales increases for asthma and COPD treatments. Antihistamine use also climbed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xI32Cmw
via IFTTT

Read More

Dr Reddy’s inks licensing deal to sell Immutep’s cancer drug

Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute the Australian company's cancer therapy, eftilagimod alfa. This significant deal, valued at up to $350 million, grants Dr. Reddy's distribution rights across most global markets, excluding North America, Europe, Japan, and Greater China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnlBJLy
via IFTTT

Read More

ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar Shaw

Biocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves financial health. The combined entity will leverage synergies across manufacturing, R&D, and commercial operations. This integration aims to accelerate launches in major markets and unlock significant growth opportunities for the unified global player.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rvdhy2q
via IFTTT

Read More

Biocon to make Biocon Biologics a wholly owned subsidiary

Biocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Biocon will acquire remaining stakes through a share swap. The deal values Biocon Biologics at $5.5 billion. This integration aims to streamline operations and enhance strategic focus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CZqtSm5
via IFTTT

Read More

Abbott asks stockists to buy only from authorised suppliers

Spurious medicines were seized in Puducherry, prompting drug maker Abbott Healthcare to warn stockists. They must buy only from authorized suppliers. The government alerted the Drug Controller General of India about the circulation of fake drugs. The All India Organisation of Chemists and Druggists issued an advisory for safe business practices. This is a serious trade alert.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npGh9NW
via IFTTT

Read More

Lupin gets USFDA nod for multiple sclerosis drug

Drug maker Lupin has secured approval from the US health regulator for its generic multiple sclerosis treatment. The company received tentative approval from the USFDA for Siponimod Tablets. This new product will be manufactured at Lupin's Pithampur facility. Siponimod Tablets are bioequivalent to Mayzent tablets and treat relapsing forms of multiple sclerosis in adults.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fWTzvcA
via IFTTT

Read More

AI and technology tackling India’s growing stroke crisis: Early detection and prevention take centre stage

India faces a mounting crisis with a 51% rise in stroke cases over the last 30 years, recording 1.25 million new strokes in 2021 alone. Yet only a quarter of Indians have access to stroke-ready hospitals. Doctors at the Medtronic X EconomicTimes.com “Stroke Pe Rok” webinar agreed that creating awareness, improving primary care screening, and leveraging emerging technology must become urgent priorities to save lives and reduce stroke burden in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3K5o8sy
via IFTTT

Read More

GSK India plans big 'reinvention', MD Bhushan Akshikar reveals

GlaxoSmithKline Pharmaceuticals is planning a major comeback in India. The company aims to double its revenue to ₹8,000 crore within the next 4-5 years. This growth will be driven by a strategic shift towards specialty drugs in oncology and liver diseases. Adult vaccination is also a key focus area.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nvbyTH2
via IFTTT

Read More

NABL accreditation sets the stage for Lords Mark Microbiotech’s growth and preventive health push

Lords Mark Microbiotech, a Lords Mark Industries subsidiary, has earned NABL accreditation. This validates their diagnostic services. The company plans to open 200 labs and 2,000 collection centers nationwide in two years. They aim to become a top pathology player. An Organ Health Score offers personalized health insights. This expansion focuses on preventive healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1HWOlN9
via IFTTT

Read More

Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment

The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qikjFVD
via IFTTT

Read More

Sun Pharma unit to invest Rs 3,000 cr on new plant in Madhya Pradesh

Sun Pharmaceutical Industries' subsidiary, Sun Pharma Laboratories Ltd, has approved a Rs 3,000 crore investment for a new greenfield formulations manufacturing facility in Madhya Pradesh. This significant expansion by the Mumbai-based drug major aims to bolster its production capabilities. The announcement comes as Sun Pharma's shares saw a slight increase on Wednesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F76BokX
via IFTTT

Read More

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutide

The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynamics in a market valued at around Rs 850 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZcG9JDB
via IFTTT

Read More

Novo Nordisk India partners with Healthify to launch AI-enabled patient support programme

Novo Nordisk India and Healthify have launched a new programme. It offers AI-assisted lifestyle guidance for people with obesity. This partnership aims to improve patient experience and treatment results. An AI assistant will help users track nutrition throughout their treatment journey.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrLORbi
via IFTTT

Read More

HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26

The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglutide. This decision comes amidst a patent infringement case filed by Novo Nordisk. Dr Reddy's is restricted from selling the drug within India until March 2026. The court acknowledged a valid challenge to Novo Nordisk's patent for semaglutide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/upk0RgU
via IFTTT

Read More

Jubilant Pharmova names Daniel J O'Connor as CEO of proprietary drugs biz

Jubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership experience in biotechnology and oncology. His expertise includes creating value around differentiated, IP-rich platforms. Previously, he was CEO of Ambrx Biopharma, where his leadership led to a significant increase in company valuation and its successful acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9ITnu4N
via IFTTT

Read More

Cough syrup row puts regulators on overdrive to test pharma products

Indian drug companies are significantly increasing product testing. This surge follows strict government rules and joint inspections by regulators. The focus is on ensuring quality after recent contamination issues. Testing volumes have jumped dramatically. Companies are investing in specialized equipment to detect toxic substances. This heightened vigilance aims to safeguard public health and maintain the integrity of India's pharmaceutical industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p2w1POC
via IFTTT

Read More

Wockhardt gets NDA status for novel antibiotic Zaynich

Wockhardt, an emerging powerhouse in the Indian pharmaceutical arena, has just scored a game-changing triumph! The US health regulator has given the green light to its New Drug Application for Zaynich, a cutting-edge antibiotic. This pivotal moment signifies the first occurrence of an Indian firm securing FDA acceptance for a New Chemical Entity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYnqwyE
via IFTTT

Read More